Ying Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ying Cheng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Aling Shen
Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China
1 shared publication Huixin Liu
Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, 350122, China; Chen Keji Academic Thought Inheritance Studio, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, 350122, China; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, 350122, China
1 shared publication- Jianfeng Chu
College of Integrative Medicine, Fujian University of Traditional Chinese Medicine
1 shared publication - Jiapeng Li
School of Mechanical Engineering, Hebei University of Technology, Tianjin, China
1 shared publication - Jun Peng
Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China
1 shared publication Linzi Long
Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, 350122, China; Chen Keji Academic Thought Inheritance Studio, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, 350122, China; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, 350122, China; Department of Geriatrics, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China
1 shared publication
Latest Publications
- Open Access
- 1 May 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 137, 111318
Qingda granule attenuates cardiac fibrosis via suppression of the TGF-β1/Smad2/3 signaling pathway in vitro and in vivo
- 1 May 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 137, 111318
Open AccessQingda granule attenuates cardiac fibrosis via suppression of the TGF-β1/Smad2/3 signaling pathway in vitro and in vivo